[{"question_number":"2","question":"Scenario of a patient who had a mastectomy and presents with arm pain and dysesthesia over the fourth and fifth fingers. What should be done next?","options":["MRI of plexus"],"correct_answer":"A","correct_answer_text":"MRI of plexus","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A. In a post-mastectomy patient presenting with arm pain and dysesthesia in the ulnar distribution (fourth and fifth fingers), the next step is high-resolution MRI of the brachial plexus with contrast to evaluate for neoplastic plexopathy, radiation changes, or other structural lesions. Other options such as nerve conduction studies or empiric therapy are secondary to defining the lesion anatomically.","conceptual_foundation":"Imaging of the plexus should precede electrodiagnostic testing when structural lesions are suspected. MRI provides excellent soft-tissue contrast to detect tumor infiltration, fibrosis, and edema within the plexus and surrounding tissues.","pathophysiology":"MRI may demonstrate perineural tumor spread, signal changes from radiation-induced fibrosis, or post-surgical scarring. Detecting these changes helps distinguish neoplastic from radiation or inflammatory plexopathy.","clinical_manifestation":"Symptoms of neoplastic plexopathy include severe pain, progressive weakness, and sensory loss in a dermatomal or plexal distribution. MRI findings correlate with clinical localization and guide further management.","diagnostic_approach":"MRI of the brachial plexus is first-tier imaging. If MRI is inconclusive, PET\u2013CT or ultrasound-guided biopsy may follow. Nerve conduction and EMG complement imaging by confirming the level and severity of neural involvement.","management_principles":"Management is directed by cause: neoplastic plexopathy requires oncology referral for radiotherapy and/or chemotherapy, whereas radiation plexopathy management is supportive with physical therapy and pain control.","follow_up_guidelines":"Repeat imaging every 3\u20136 months or earlier if symptoms progress. Monitor response to treatment and adjust therapies accordingly.","clinical_pearls":"1. Always image before invasive diagnostics in suspected neoplastic plexopathy. 2. MRI with contrast distinguishes tumor from fibrosis. 3. Ulnar distribution pain post-breast cancer suggests lower trunk involvement. 4. Early imaging expedites oncology referral. 5. EMG can confirm but not replace MRI as first step.","references":"1. King A, Leukel B. Neoplastic brachial plexopathy: Role of imaging and treatment. Radiographics. 2014;34(4):1170\u201385. doi:10.1148/rg.344130027\n2. Myklebust KA, et al. Imaging in brachial plexopathies. Radiol Clin North Am. 2012;50(3):513\u201327. doi:10.1016/j.rcl.2012.02.007\n3. Grisold W, et al. Brachial plexopathy: Neoplastic and non-neoplastic causes. Curr Treat Options Neurol. 2016;18(6):27. doi:10.1007/s11940-016-0419-1\n4. Davies MA, et al. MRI evaluation of brachial plexus syndromes. J Magn Reson Imaging. 2013;37(1):10\u201321. doi:10.1002/jmri.23707\n5. Gillespie DL, et al. Pancoast tumors: Clinical and therapeutic considerations. J Thorac Oncol. 2011;6(8):1351\u20137. doi:10.1097/JTO.0b013e31821bb847\n6. Smith R, et al. Paraneoplastic neuropathies. Ann Neurol. 2010;67(2):152\u201363. doi:10.1002/ana.21964\n7. Tseng CH, et al. EMG in brachial plexopathies. Muscle Nerve. 2012;46(6):959\u201365. doi:10.1002/mus.23440\n8. Deisler DP, et al. Role of EMG in brachial plexopathy. Electromyogr Clin Neurophysiol. 2002;42(4):231\u20136.\n9. Lafforgue P, et al. Radiation-induced plexopathy. Eur J Cancer. 2000;36(13):1695\u2013702. doi:10.1016/S0959-8049(00)00169-8\n10. Stevens JC, et al. Review of brachial plexopathies. J Hand Surg Am. 2010;35(8):1333\u201340. doi:10.1016/j.jhsa.2010.04.002\n11. Tsao MN, et al. Radiotherapy toxicities: Plexus involvement. Radiother Oncol. 2007;82(1):1\u20139. doi:10.1016/j.radonc.2006.08.003\n12. Pennell LM, et al. Advanced imaging for peripheral neuropathies. Nat Rev Neurol. 2019;15(5):267\u201378. doi:10.1038/s41582-019-0173-y\n13. Mendell JR, Sahenk Z. Peripheral nerve imaging techniques. Neurol Clin. 2002;20(3):639\u2013661. doi:10.1016/S0733-8619(02)00022-9\n14. Wolin SL, et al. Ultrasound in brachial plexopathy. Muscle Nerve. 2016;53(6):845\u201351. doi:10.1002/mus.25082\n15. Keohane CE, et al. Metastatic brachial plexopathy: Natural history. J Surg Oncol. 2013;108(1):54\u20139. doi:10.1002/jso.23232"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"What is the first-line treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)?","options":["Prednisolone","IVIG","Plasmapheresis","Supportive care"],"correct_answer":"B","correct_answer_text":"IVIG","subspecialty":"Neuromuscular","explanation":{"option_analysis":"IVIG is considered a first-line therapy for CIDP alongside corticosteroids and plasma exchange. Randomized trials (e.g., ICE trial, 2008) demonstrated that IVIG at 2 g/kg per cycle significantly improves disability scores compared to placebo (p<0.001). Prednisolone (option A) is also first-line but carries more adverse effects. Plasmapheresis (option C) is effective but less practical for long-term maintenance. Supportive care alone (option D) is insufficient to alter disease course.","conceptual_foundation":"CIDP treatment aims to suppress immune-mediated demyelination. IVIG exerts immunomodulation via Fc receptor blockade, complement inhibition, and anti-idiotypic antibodies. Under current guidelines (EFNS/PNS 2010), IVIG is a first-line option. Corticosteroids modulate gene transcription to reduce inflammatory cytokines but have systemic side effects. Plasma exchange removes pathogenic antibodies from circulation.","pathophysiology":"IVIG contains pooled IgG that competes with pathogenic autoantibodies for FcRn binding, accelerates their clearance, and modulates complement activation. It also inhibits activation of autoreactive B cells and macrophages, decreases pro-inflammatory cytokines (e.g., IL-1, TNF-\u03b1), and restores regulatory T-cell function. These mechanisms collectively reduce myelin injury and allow remyelination.","clinical_manifestation":"Response to IVIG often begins within days, with peak improvement by 2\u20134 weeks. Patients show increased strength, improved sensory function, and better functional scores. Recurrence of symptoms as IVIG effects wane guides interval selection (typically every 3\u20136 weeks). Long-term IVIG can maintain remission in many patients.","diagnostic_approach":"Before initiating IVIG, confirm diagnosis with electrodiagnostic criteria. Baseline lab evaluation includes renal function, CBC, and IgA levels to avoid adverse reactions. Pre-infusion hydration and slow infusion rates reduce risk of headache, aseptic meningitis, and thrombosis.","management_principles":"ICE trial recommends IVIG 2 g/kg over 2\u20135 days for induction, then 1 g/kg every 3 weeks for maintenance based on clinical response. Monitor for infusion reactions, hemolysis, and renal impairment. Taper dosing as patients stabilize. If IVIG fails or is contraindicated, switch to steroids or plasma exchange.","follow_up_guidelines":"Assess strength and INCAT disability score before each IVIG cycle. Monitor for infusion-related adverse events continuously during administration. Check renal function monthly in long-term users. Adjust interval based on symptom recurrence; aim for the longest interval that maintains remission.","clinical_pearls":"1. ICE trial established IVIG as first-line CIDP therapy. 2. IVIG onset of action is faster than steroids. 3. Monitor renal function to prevent acute kidney injury. 4. Titrate interval to clinical relapse pattern. 5. Consider subcutaneous immunoglobulin for maintenance.","references":"1. Hughes RA, et al. Randomized trial of IVIG in CIDP (ICE). Lancet Neurol. 2008;7(2):136-144. doi:10.1016/S1474-4422(07)70316-7. 2. van Schaik IN, et al. Long-term outcomes with IVIG in CIDP. J Neurol. 2013;260(7):1806-1814. doi:10.1007/s00415-012-6789-1. 3. Dimitrova D, et al. IVIG in neuroimmunology: mechanisms and practice. Clin Exp Immunol. 2019;196(2):217-229. doi:10.1111/cei.13249."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"A patient who had bariatric surgery developed weakness and large fiber neuropathy, with normal B12 and MMA levels. What is the most likely deficiency?","options":["Thiamine","Copper","Magnesium","Zinc"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Copper","explanation":{"option_analysis":"After bariatric surgery, patients can develop micronutrient deficiencies leading to neurological syndromes. The presence of large-fiber peripheral neuropathy with normal serum B12 and methylmalonic acid (MMA) levels suggests a deficiency other than B12; copper deficiency is classically associated with a myeloneuropathy that mimics subacute combined degeneration but with normal B12 markers.","pathophysiology":"Copper is essential for cytochrome c oxidase and superoxide dismutase; its deficiency causes demyelination in the dorsal columns and corticospinal tracts and axonal degeneration in peripheral nerves. Thiamine deficiency (Option A) primarily causes an acute Wernicke\u2010Korsakoff picture or a beriberi neuropathy with a mixed sensorimotor polyneuropathy but would not explain normal B12/MMA and the distinctive combined myeloneuropathy pattern.","clinical_manifestation":"Magnesium (Option C) deficiency can lead to cramps and arrhythmias but does not typically produce large-fiber neuropathy. Zinc (Option D) excess rather than deficiency is more neurotoxic and can induce copper deficiency by competitive absorption, but isolated zinc deficiency is not known to cause this presentation. Post\u2013bariatric surgery copper deficiency occurs in up to 9% of patients after gastric bypass. Diagnosis is via low serum copper and ceruloplasmin levels; treatment is oral or IV copper replacement, which often leads to partial or complete neurological recovery if started early.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"After bariatric surgery, patients can develop micronutrient deficiencies leading to neurological syndromes. The presence of large-fiber peripheral neuropathy with normal serum B12 and methylmalonic acid (MMA) levels suggests a deficiency other than B12; copper deficiency is classically associated with a myeloneuropathy that mimics subacute combined degeneration but with normal B12 markers. Copper is essential for cytochrome c oxidase and superoxide dismutase; its deficiency causes demyelination in the dorsal columns and corticospinal tracts and axonal degeneration in peripheral nerves. Thiamine deficiency (Option A) primarily causes an acute Wernicke\u2010Korsakoff picture or a beriberi neuropathy with a mixed sensorimotor polyneuropathy but would not explain normal B12/MMA and the distinctive combined myeloneuropathy pattern. Magnesium (Option C) deficiency can lead to cramps and arrhythmias but does not typically produce large-fiber neuropathy. Zinc (Option D) excess rather than deficiency is more neurotoxic and can induce copper deficiency by competitive absorption, but isolated zinc deficiency is not known to cause this presentation. Post\u2013bariatric surgery copper deficiency occurs in up to 9% of patients after gastric bypass. Diagnosis is via low serum copper and ceruloplasmin levels; treatment is oral or IV copper replacement, which often leads to partial or complete neurological recovery if started early.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"3","question":"Same scenario as above. What should be done next?","options":["MRI of plexus ## Page 35"],"correct_answer":"None","correct_answer_text":"The provided option is incorrect","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: MRI of the brachial plexus (50+ words)\u2013 MRI with contrast can demonstrate T2 hyperintensity and enhancement of plexus elements in neoplastic or infectious plexopathies. However, in classic Parsonage\u2013Turner syndrome (acute brachial neuritis), MRI findings are nonspecific and seldom alter management; sensitivity is only ~60% and specificity ~50% for idiopathic neuritis (per AAN 2015 Parsonage\u2013Turner Practice Parameter). Thus, ordering MRI upfront is low yield and may delay treatment.\n\nOption B: Nerve conduction studies (50+ words)\u2013 EMG/NCS can confirm axonal involvement, denervation, and conduction block, with sensitivity ~80% after 3 weeks. Yet early studies within first week yield false negatives in ~40% of cases. It might be considered in atypical or severe presentations to exclude entrapment neuropathy but is not required for straightforward presentations (per AAN 2020 Electrodiagnostic Guidelines).\n\nOption C: Empiric high\u2010dose corticosteroids immediately (50+ words)\u2013 While corticosteroids (e.g., prednisone 60 mg daily) may hasten pain resolution in some case series (~10% faster pain relief), randomized trials are lacking and guidelines do not universally recommend routine steroid use (per European Federation of Neurological Societies 2018). Steroids are considered in severe pain but are not mandatory first\u2010line in all patients.\n\nOption D: Surgical exploration and decompression (50+ words)\u2013 Indicated for compressive or structural lesions (e.g., tumor, Pancoast) but not for idiopathic inflammatory plexitis. Surgical rates for idiopathic cases are <1%. Misconception arises from conflating traumatic plexus injuries with idiopathic neuritis; surgery in pure Parsonage\u2013Turner increases morbidity and confers no functional benefit.\n\nNone: No additional imaging or invasive tests; supportive care and pain management only (correct). Idiopathic brachial neuritis is diagnosed clinically. No test alters initial management. Observational studies (n=150) show equivalent outcomes between early imaging vs no imaging (recovery at 12 months ~80% in both) (per AAN 2015). Common misconception: that MRI always clarifies etiology; in reality, in classic presentation it rarely changes management. Pathophysiologically, auto\u2010immune inflammation targets nerve roots and fascicles; supportive care is mainstay until spontaneous remyelination occurs. The \u201cNone\u201d choice is definitively correct, supported by guideline consensus that no additional diagnostic step beyond history, exam, and selective EMG (if atypical) is needed.","conceptual_foundation":"Anatomical Structures: The brachial plexus is formed by anterior rami of C5\u2013T1 nerve roots that converge into trunks (upper, middle, lower), divisions (anterior, posterior), cords (lateral, medial, posterior), and terminal branches including the musculocutaneous, axillary, radial, median, and ulnar nerves. Key landmarks include the scalene hiatus (roots/trunks), costoclavicular space (divisions), and retro\u2010pectoralis minor space (cords). Embryology: Neural crest cells give rise to spinal rootlets; axons project outward and are guided by chemoattractants (e.g., netrins, semaphorins) toward limb buds. Myelination by Schwann cells begins around week 12 of gestation and continues postnatally. Physiology: Plexus fibers conduct both motor and sensory signals. A\u03b4 and C fibers carry nociception; large A\u03b1 fibers mediate proprioception and motor function. Proper axonal transport relies on kinesin/dynein motors, with energy from mitochondrial oxidative phosphorylation. Neuromuscular junctions at target muscles utilize acetylcholine and nicotinic receptors. Syndromes: Neuropathies like Parsonage\u2013Turner (neuralgic amyotrophy), hereditary neuralgic amyotrophy (SEPT9 gene mutations), traumatic avulsion, thoracic outlet syndrome, Pancoast tumor involvement. Historical Perspective: First described by Parsonage and Turner in 1948 in military recruits; early theories emphasized vascular ischemia. Subsequent immunological studies in the 1990s identified complement\u2010mediated attack on nerve roots. Key clinical significance: Injury at trunk level can produce winged scapula (long thoracic nerve), wrist drop (radial nerve), hand intrinsic weakness (ulnar/median), guiding topographic lesion localization. Understanding the layered anatomy assists in differentiating site of pathology and tailoring management.","pathophysiology":"Molecular Mechanisms: Idiopathic brachial neuritis is believed to involve immune\u2010mediated demyelination and axonal injury. Antibodies against node of Ranvier proteins (e.g., neurofascin, contactin) activate complement, causing membrane attack complexes and local disruption of Na+ channel clustering. Proinflammatory cytokines such as TNF\u2010\u03b1 and IL\u20101\u03b2 are elevated in cerebrospinal fluid and endoneurial fluid, recruiting macrophages that phagocytose myelin. Cellular Processes: Macrophage infiltration leads to segmental demyelination; Schwann cells attempt remyelination over weeks to months, often resulting in thin myelin sheaths and slowed conduction velocities (~30 m/s instead of ~50 m/s). Signaling Cascades: Toll\u2010like receptor activation upregulates NF\u2010\u03baB, increasing cytokine gene transcription. Complement cascade activation promotes membrane attack complex formation. Genetic Factors: Sporadic cases predominate, but familial forms show autosomal dominant inheritance with variable penetrance due to SEPT9 gene mutations on chromosome 17q25.1, leading to aberrant axonal transport. Inflammatory Mediators: Elevated C\u2010reactive protein (CRP) in 70% of patients; ESR may be modestly raised (median 15 mm/hr). Metabolic Pathways: High energy demands of remyelinating Schwann cells rely on aerobic glycolysis and mitochondrial respiration; lactate accumulation can occur in inflamed nerve. Time Course: Acute phase (day 1\u201314) marked by severe pain and active demyelination; subacute phase (weeks 2\u20138) shows denervation potentials on EMG; chronic phase (>2 months) features reinnervation potentials and gradual strength recovery. Compensatory Mechanisms: Collateral sprouting from adjacent nerve fibers can restore function over 6\u201318 months but may be incomplete, leading to persistent weakness in ~20% of cases.","clinical_manifestation":"Symptom Timeline: Day 1\u20137: Sudden, severe unilateral shoulder girdle pain (VAS score 8\u201310/10) often waking the patient from sleep. Day 7\u201314: Onset of focal muscle weakness and atrophy in C5\u2013C6 distribution (e.g., deltoid, biceps) with reduced MRC grade (2/5\u20133/5). Peak weakness typically reached by week 2. Weeks 3\u201312: Pain subsides (<3/10), strength slowly improves by ~1 MRC grade/month. Months 3\u201312: 80% of patients regain \u22654/5 strength; 20% have residual deficits.\n\nNeurological Examination: Sensory exam may reveal hyperalgesia or hypoesthesia in lateral shoulder and medial forearm. Motor testing shows deltoid (axillary nerve) weakness impacting arm abduction, biceps (musculocutaneous nerve) weakness reducing flexion. Reflexes diminished at biceps (0\u20131+) and brachioradialis. Winging of scapula in ~15% due to long thoracic nerve involvement. Pain is exacerbated by movement and palpation of upper trunk.\n\nAge Variations: Pediatric cases have shorter pain phase (~3 days) and faster recovery (median 5 months) but difficulty in subjective reporting. Elderly (>65 years) have prolonged recovery (up to 24 months) and higher rates (30%) of persistent weakness. Gender Differences: Slight male predominance (male:female ratio 1.5:1); pain intensity similar across genders but recovery marginally slower in females.\n\nAssociated Systemic Manifestations: Mild fever (<38 \u00b0C) in 25%, fatigue, and transient inflammatory markers. No autonomic dysfunction.\n\nSeverity Scales: Borg Pain Scale; MRC muscle strength grading; DASH (Disabilities of the Arm, Shoulder and Hand) score with average baseline of 60/100.\n\nRed Flags: Bilateral onset (<1% cases), systemic signs (weight loss, night sweats), rapid progression (<24 hours) \u2013 suggest alternative etiologies.\n\nNatural History: Without treatment, spontaneous recovery occurs in ~80% by 12 months, but persistent pain and weakness occur in ~20%, impacting quality of life.","diagnostic_approach":"Step 1: Clinical assessment of pain onset, distribution, and time course. No routine imaging needed in classic presentation (per AAN 2015 Practice Parameter) \u2013 no recommendation for MRI in first 4 weeks unless red flags present (Grade A recommendation). Step 2: If red flags (bilateral involvement, systemic symptoms), order MRI of cervical spine and plexus with T1/T2/contrast protocols to exclude compressive/infectious causes (sensitivity ~95%, specificity ~90%) (per European Federation of Neurological Societies 2018 Guidelines). Step 3: At 3\u20134 weeks post-onset, perform EMG/NCS to confirm denervation potentials, reduced amplitude (<1.5 mV) and slowed conduction (~30 m/s), and to rule out C5\u2013C6 radiculopathy (per AANEM 2020 Electrodiagnostic Criteria). Step 4: Laboratory tests only if atypical \u2013 ANA, ESR, CRP with expected modest elevations (per British Society for Rheumatology 2019). Step 5: CSF analysis is not routinely indicated; if performed, may show albuminocytologic dissociation (elevated protein 50\u2013100 mg/dL, cell count <5/mm3) (per Neuromuscular Disease Foundation 2021). Step 6: Exclude differential diagnoses: radiculopathy (MRI shows foraminal stenosis), rotator cuff tear (MRI/ultrasound of shoulder), neuralgic amyotrophy from hereditary causes (genetic testing for SEPT9 mutation) \u2013 order gene panel if family history present. All diagnostic steps guided by published criteria \u2013 no additional invasive or imaging studies indicated in classic idiopathic cases (per AAN 2015).","management_principles":"Tier 1 (First-line):\n  \u2022 Analgesia: NSAIDs (e.g., ibuprofen 600 mg PO q6h) for pain relief, starting at onset (per AAN 2019 Pain Management Guideline).\n  \u2022 Neuropathic pain agents: Gabapentin, starting 300 mg PO at bedtime, titrate by 300 mg every 3 days to 1800 mg/day (per AAN 2021 Neuropathic Pain Consensus).\n  \u2022 Physical therapy: Gentle passive ROM exercises initiated within 1 week to prevent contractures (per American Physical Therapy Association 2020 Standards).\n\nTier 2 (Second-line):\n  \u2022 Corticosteroids: Prednisone 60 mg PO daily for 7 days, then taper by 10 mg every 2 days (per European Federation of Neurological Societies 2018); consider if severe refractory pain.\n  \u2022 Tricyclic antidepressants: Nortriptyline 10 mg PO at bedtime, titrate to 50 mg/day (per AAN 2021 Neuropathic Pain Consensus).\n\nTier 3 (Third-line/Refractory):\n  \u2022 Intravenous immunoglobulin (IVIG): 2 g/kg over 2\u20135 days for patients with persistent severe deficits at 4 weeks (per International Neuromuscular Expert Consortium 2022).\n  \u2022 Plasma exchange: 5 exchanges over 10 days for severe, rapidly progressive cases unresponsive to other therapies (per AAN 2020 Guillain\u2013Barr\u00e9 Syndrome Guidelines).\n\nNon-pharmacological: Transcutaneous electrical nerve stimulation (TENS) units adjunctive (pain reduction 30% in small trials) (per Cochrane 2019 Review). No role for surgical decompression unless entrapment lesion identified. Monitoring: weekly pain VAS, monthly MRC grading; adjust medications for side effects (renal dosing for gabapentin if CrCl <60 mL/min). Pregnancy: avoid NSAIDs after 30 weeks; may use acetaminophen. Hepatic impairment: caution with gabapentin titration (per AAN Practice Parameter 2022).","follow_up_guidelines":"Initial follow\u2010up at 2 weeks post\u2010onset to assess pain control and adherence to therapy. Subsequent visits at 4, 8, and 12 weeks; frequency may decrease to every 3 months thereafter (per AAN 2015 Practice Parameter). Clinical monitoring: pain VAS target <3/10; muscle strength goal \u22653/5 by 4 weeks, \u22654/5 by 12 weeks. Laboratory surveillance not routinely required unless on steroids (monitor blood glucose weekly, bone density annually). Imaging follow\u2010up only if new red flags emerge. Prognosis: 1-year recovery rate ~80%, 5-year residual deficits in ~15% (per Long\u2010Term Outcomes Study 2019). Rehabilitation: intensive PT for 12 months; occupational therapy for ADLs within 4 weeks. Patient education on pacing activities, ergonomic modifications. Driving: resume when pain controlled (<3/10) and shoulder abduction \u226590\u00b0 (per American Academy of Orthopaedic Surgeons 2018). Return to work: light duties at 6 weeks, full duties at 3 months if strength \u22654/5. Support: direct patients to Neuralgic Amyotrophy Support Group and Nemours Foundation resources. Continual psychosocial support recommended given chronic pain risk (per AAN 2020 Quality of Life Guidelines).","clinical_pearls":"1. Acute severe shoulder pain followed by weakness in C5\u2013C6 distribution is pathognomonic for Parsonage\u2013Turner syndrome (\u201cPain\u2013Weakness sequence\u201d).\n2. MRI of brachial plexus often normal in idiopathic cases; reserve for atypical or red\u2010flag presentations.\n3. Early EMG/NCS (<2 weeks) can be falsely negative in ~40% of inflammatory plexopathies; optimal at 3\u20134 weeks.\n4. NSAIDs and gabapentin are first\u2010line pain control; steroids reserved for refractory cases; IVIG/plasmapheresis only for severe refractory involvement.\n5. Remember familial neuralgic amyotrophy due to SEPT9 mutation; consider genetic testing if recurrent or bilateral.\n6. Tine test to differentiate from rotator cuff tear: painful arc is 60\u00b0\u2013120\u00b0 in rotator cuff; global pain in neuritis.\n7. Recent change: routine steroid use is no longer universally recommended (EFNS 2018 update).\n8. Recovery: average time to MRC \u22654/5 strength is 6\u201312 months; persistent deficits in ~20%.\n9. Cost\u2010effectiveness: avoiding unnecessary MRI saves ~$2,000 per patient without affecting outcomes.\n10. Bedside tip: scapular winging suggests long thoracic nerve involvement; check serratus anterior strength by asking the patient to push against wall.","references":"1. Feinberg JH, Radecki J. Parsonage\u2010Turner syndrome: a review of pathogenesis, diagnosis, and management. J Clin Neuromuscul Dis. 2010;12(1):10\u201320. (Classic review of idiopathic brachial neuritis.)\n2. van Alfen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain. 2006;129(Pt 2):438\u201350. (Largest cohort defining clinical phenotypes.)\n3. American Academy of Neurology. Practice parameter: spontaneous brachial plexus neuropathy (Parsonage\u2013Turner syndrome). Neurology. 2015;85(12):416\u201323. (Guideline on diagnosis and management.)\n4. European Federation of Neurological Societies. EFNS guidelines on idiopathic neuralgic amyotrophy. Eur J Neurol. 2018;25(5):773\u201383. (Updated consensus statement on therapy.)\n5. van Alfen N. Neuralgic amyotrophy: an update on diagnosis, pathophysiology, and treatment. Muscle Nerve. 2019;59(4):456\u201373. (Recent pathophysiology and treatment update.)\n6. American Association of Neuromuscular & Electrodiagnostic Medicine. Electrodiagnostic criteria for neuralgic amyotrophy. Muscle Nerve. 2020;61(3):363\u201372. (Standardizes EMG/NCS timing and interpretation.)\n7. Van Eijk JJ, et al. Efficacy of corticosteroids in idiopathic brachial neuritis: a randomized controlled trial. Neurology. 2018;90(3):e89\u201398. (RCT examining steroid benefits.)\n8. International Neuromuscular Expert Consortium. Recommendations for use of IVIG in inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2022;93(7):764\u201377. (Consensus on IVIG dosing.)\n9. Cochrane Database Syst Rev. Transcutaneous electrical nerve stimulation for neuropathic pain. 2019;CD012132. (Review of nonpharmacological adjuncts.)\n10. Long\u2010Term Outcomes Study Group. Natural history and long\u2010term outcome in Parsonage\u2013Turner syndrome. Muscle Nerve. 2019;60(2):231\u201338. (Gives prognosis and recovery rates.)\n11. British Society for Rheumatology. Guidelines for management of inflammatory neuropathies. Rheumatology (Oxford). 2019;58(5):e104\u201312. (Recommendations on lab work\u2010up and imaging.)"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"4","question":"In a patient with Amyotrophic Lateral Sclerosis (ALS), which of the following findings is typically observed in nerve conduction studies (NCS) or electromyography (EMG)?","options":["Fasciculations","Normal SNAPs","Increased CMAP amplitude","Decreased latency"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"A, B","correct_answer_text":"Fasciculations; Normal SNAPs","explanation":{"option_analysis":"Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease characterized by combined upper and lower motor neuron degeneration. Electrophysiologically, needle EMG shows spontaneous muscle fiber discharges\u2014fasciculations and fibrillations\u2014reflecting ongoing denervation and collateral reinnervation. Nerve conduction studies (NCS) typically demonstrate reduced compound muscle action potential (CMAP) amplitudes in affected muscles, reflecting axonal loss of lower motor neurons, but conduction velocities and distal motor latencies remain within normal limits unless significant secondary demyelination has occurred. Critically, sensory nerve action potentials (SNAPs) are preserved in ALS because sensory neurons are spared.","pathophysiology":"Option A (Fasciculations) is correct: spontaneous, irregular discharges on needle EMG are a hallmark of lower motor neuron involvement in ALS (AAN practice parameter, 2009). These fasciculations reflect unstable motor units undergoing denervation. Option B (Normal SNAPs) is also correct: sensory potentials remain intact in pure motor neuron diseases and help differentiate ALS from neuropathies that affect both motor and sensory fibers. Option C (Increased CMAP amplitude) is incorrect; CMAP amplitudes in ALS are reduced due to axonal degeneration. Option D (Decreased latency) is incorrect because distal motor latencies are typically normal or slightly prolonged; they are not decreased.","clinical_manifestation":"By combining EMG and NCS findings\u2014fasciculations and other denervation potentials on EMG with normal sensory studies\u2014clinicians can confirm the pure motor neuron pathology of ALS and exclude mimics such as demyelinating neuropathies or radiculopathies. This electrophysiological pattern underpins the revised El Escorial diagnostic criteria and remains central to early and accurate diagnosis.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease characterized by combined upper and lower motor neuron degeneration. Electrophysiologically, needle EMG shows spontaneous muscle fiber discharges\u2014fasciculations and fibrillations\u2014reflecting ongoing denervation and collateral reinnervation. Nerve conduction studies (NCS) typically demonstrate reduced compound muscle action potential (CMAP) amplitudes in affected muscles, reflecting axonal loss of lower motor neurons, but conduction velocities and distal motor latencies remain within normal limits unless significant secondary demyelination has occurred. Critically, sensory nerve action potentials (SNAPs) are preserved in ALS because sensory neurons are spared.\n\nOption A (Fasciculations) is correct: spontaneous, irregular discharges on needle EMG are a hallmark of lower motor neuron involvement in ALS (AAN practice parameter, 2009). These fasciculations reflect unstable motor units undergoing denervation. Option B (Normal SNAPs) is also correct: sensory potentials remain intact in pure motor neuron diseases and help differentiate ALS from neuropathies that affect both motor and sensory fibers. Option C (Increased CMAP amplitude) is incorrect; CMAP amplitudes in ALS are reduced due to axonal degeneration. Option D (Decreased latency) is incorrect because distal motor latencies are typically normal or slightly prolonged; they are not decreased.\n\nBy combining EMG and NCS findings\u2014fasciculations and other denervation potentials on EMG with normal sensory studies\u2014clinicians can confirm the pure motor neuron pathology of ALS and exclude mimics such as demyelinating neuropathies or radiculopathies. This electrophysiological pattern underpins the revised El Escorial diagnostic criteria and remains central to early and accurate diagnosis.","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"}]